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Meditation is commonly thought to induce physiologically quiescent states, as evidenced
by decreased autonomic parameters during the meditation practice including reduced
heart rate, respiratory rate, blood pressure, skin conductance, and increased alpha
activity in the electroencephalogram. Preliminary empirical support for this idea was
provided in a case report by Dimsdale and Mills (2002), where it was found that
meditation seemed to regulate increased levels of cardiovascular arousal induced by
bolus isoproterenol infusions. In that study, while meditating, a self-taught meditator
exhibited unexpected decreases in heart rate while receiving moderate intravenous
doses of the beta adrenergic agonist isoproterenol. This effect was no longer observed
when the individual received isoproterenol infusions while not meditating. The current
study was designed to explore this phenomenon empirically in a group of formally trained
meditators. A total of 15 meditators and 15 non-meditators individually matched on age,
sex, and body mass index were recruited. Participants received four series of infusions
in a pseudorandomized order: isoproterenol while meditating (or during a relaxation
condition for the non-meditators), isoproterenol while resting, saline while meditating
(or during a relaxation condition for the non-meditators), and saline while resting. Heart
rate was continuously measured throughout all infusions, and several measures of heart
rate were derived from the instantaneous cardiac waveform. There was no evidence
at the group or individual level suggesting that meditation reduced the cardiovascular
response to isoproterenol, across all measures. These results suggest that meditation is
not associated with increased regulation of elevated cardiac adrenergic tone.
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Introduction
Meditation is a form of mental training that has been practiced for thousands of years, and
that can be conceptualized as a family of complex emotional and attentional regulatory training
regimens developed for various ends, including the cultivation of well-being and emotional balance
(Davidson et al., 1976; Ekman et al., 2005; Brefczynski-Lewis et al., 2007). Meditation has also
been defined as involving a process of intentional self-regulation of attention, in which attention
is directed from a combination of external and internal stimuli to a primarily internally perceptive
state (Astin et al., 2003; Bonadonna, 2003). Traditional philosophies emphasize that anyone
can learn to meditate (Taimni, 1961), and that through repeated practice meditation provides
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long-term effects that outlast the confines of individual
meditative states (Nyanaponika, 1969; Ahir, 1999; Burley, 2000).
A central tenet of early investigations into the effects of
meditation has been that meditation induces a physiologically
quiescent bodily state. This was based on initial reports
of decreases in autonomic parameters such as heart rate,
respiratory rate, blood pressure, skin conductance, and
adrenergic reactivity, as well as increased levels of alpha activity
in the electroencephalogram during the practice of meditation
[mostly Transcendental Meditation (TM)] (Wallace et al.,
1971; Orme-Johnson, 1973; Beary and Benson, 1974; Farrow
and Hebert, 1982; Hoffman et al., 1982; Jevning et al., 1992;
Travis and Wallace, 1997; Aftanas and Golocheikine, 2002;
Aftanas and Golosheykin, 2005). Early researchers described
this pattern of autonomic responses as an integrated “relaxation
response” (Benson et al., 1974). More recently, investigations
have continued finding reductions in physiological parameters
such as heart rate and blood pressure occur during the acute
meditation practice (Telles et al., 1995; Barnes et al., 1999;
Solberg et al., 2004) as well as following practice over longer
periods of time (Barnes et al., 2004; Harinath et al., 2004). Similar
effects have also been reported for more secular and abbreviated
protocols such as an 8 week training in Mindfulness Based Stress
Reduction, which incorporates instruction in meditation as well
as teaches cognitive and other approaches to enhance stress
reduction (Hughes et al., 2013).
Although the notion that meditation results in physiologically
quiescent states is well established, the extent to which meditative
practices exert such effects is unknown. Early investigations of
yogis in India who claimed to be able to exert considerable
voluntary control of the heart (some claimed to be able to
stop the heart) revealed limited support for this idea. At
best, some individuals were able to exert transient bradycardia,
or reductions in heart rate by engaging in combinations of
posture manipulation, muscular contraction and breath holding
(including the Valsalva maneuver, or “bearing down,” which
elicits a complex pattern of reflexes including tachy/bradycardia
and hyper/hypotension) (Wenger et al., 1961). Subsequent
studies have reported mixed results, primarily for different yoga
adepts (Fenz and Plapp, 1970; Kothari et al., 1973).More recently,
shorter term changes in the ability to reduce the resting heart
rate have been reported (Telles et al., 2004). The perception
that meditation and yoga confers an increased cardiac regulatory
capability has persisted, despite this heterogeneous literature.
Preliminary empirical support via a case study approach
suggested a novel effect of meditation on the ability to regulate
increased levels of cardiovascular arousal. Dimsdale and Mills
(2002) reported a case study in which a female meditator was
randomly recruited to participate in a standardized isoproterenol
challenge as a control subject in their studies of sympathetic
nervous system regulation in hypertension (Dimsdale et al., 1988;
Mills et al., 1998). Isoproterenol stimulates peripheral beta 1
and beta 2 adrenergic receptors equally, and when administered
intravenously results in rapid and transient increases in heart
rate, contractility and bronchodilation, as well as decreases in
diastolic blood pressure. The protocol involved administration
of a standard isoproterenol sensitivity test, involving sequentially
increasing doses of intravenous isoproterenol. Halfway into the
infusions the woman spontaneously started meditating, and
continued to meditate during the infusions. At the time of the
isoproterenol challenge the investigators did not know she was
a meditator, but noticed afterwards that after the fourth dose (1
mcg) her heart rate had begun to decrease, in stark contrast to the
expected increase. They report that at the highest dose (4 mcg),
when the expected heart rate response was a 21 beats per minute
(bpm) increase above baseline, they observed a 17 bpm decrease
below baseline. When this unexpected result was mentioned,
the participant stated that she had decided to start meditating
halfway into the experiment. Suspecting that her meditation
practice had interfered with the isoproterenol response, she was
asked to return 2 weeks later and repeat the challenge, with
explicit instructions to avoid meditating during the infusions.
Her heart rate response to the subsequent infusion protocol
appeared entirely consistent with the typical laboratory response
to isoproterenol at rest (i.e., an approximately 20 bpm increase
above baseline at the highest dose). This individual reported a
self-taught meditation practice for many years, and that she did
not practice any particular tradition of meditation.
The current study was designed to investigate whether there
is an effect of meditation on attenuating adrenergically mediated
increases in sympathetic arousal, using an empirical group study
approach. We recruited formally trained meditators with at least
several years of experience, and examined autonomic parameters
of sympathetic arousal during meditation and resting conditions,
during the application of isoproterenol and saline infusions.
To examine whether such a putative effect was specific to a
meditation practice or was a generic ability inherent to humans
more generally, we also recruited a group of individually matched
non-meditators, and tested them under relaxation and resting
conditions.
We hypothesized that the practice of meditation would be
specifically associated with an enhanced ability to regulate body
states occurring in the context of acute physiological arousal. To
test this hypothesis, the impact of a meditation practice on the
cardiovascular response to isoproterenol was assessed. Several
specific predictions derive from our hypothesis: (1) In the face of
isoproterenol infusions, during a meditation practice meditators
would display lower isoproterenol induced heart rate increases
than during a non-meditation condition. (2) Meditators would
demonstrate lower heart rate increases during a meditation
practice than non-meditators during a relaxation practice. (3)
Heart rate reductions in the meditators would be specific to
meditation, i.e., meditators and non-meditators would have
equivalent heart rate responses to isoproterenol at rest (when not
engaging in meditation or relaxation strategies).
Methods
Participants
Fifteen meditators and fifteen non-meditators participated in
the study. Each non-meditator was individually matched to a
corresponding meditator based on three criteria: age, gender,
and body mass index (see Table 1). Meditators were considered
eligible for participation if they reported a continuous (daily or
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TABLE 1 | Meditator and non-meditator demographic data.
Meditators (M) Non-meditators (NM)
Sex 10 Men, 5 Women 10 Men, 5 Women
Age (yrs) 44.7±13.2 44.0±13.7
Body Mass Index 24.5±4.6 25.5±4.0
Race 15 Caucasian
American
14 Caucasian American,
1 Asian American
Education (years) 17.3±2.2 15.9±2.3
Beck Anxiety Inventory score 5.1±3.4 3.5±2.9
Beck Depression Inventory score 4.3±4.6 3.7±5.3
Meditation practice (years)* 10.8±10.8 0±0
Cumulative meditation practice
(hours)*
4947±6251 0±0
Retreat experience (days)** 19±14 0±0
CD25 (micrograms) 4.48±1.5 4.72±2.2
Practice similarity: iso +
meditation/relaxation
3.5±1.1 3.4±1.1
Practice similarity: saline +
meditation/relaxation
3.7±1.1 3.8±0.8
Chronotropic Dose 25 (CD25): isoproterenol dose (mcg) required to increase the heart
rate by 25 beats per minute. Mean ± SD. *p < 0.01, **p < 0.05. Means ± standard
deviation. Iso, isoproterenol.
near daily) meditation practice during the previous 2 years, and if
they had also attended one or more weeklong meditation retreats
within the previous year. Using this criteria, 11 of the recruited
meditators were Vipassana practitioners, and the other four
meditators were Kundalini practitioners. Non-meditators were
considered eligible for participation if they had never received
formal meditation training in meditation or yoga and did not
practice self-taught meditation.
All participants were screened for the presence of any
neurological, psychiatric, cardiac or respiratory disease during
a detailed phone interview, and were excluded if they reported
a history of disease in any of these categories. None of the
study participants were smokers, and none of the women took
oral contraceptives or were pregnant, as assessed via urine
pregnancy test. Each participant demonstrated a normal 12
lead electrocardiogram (EKG), as assessed by a board certified
cardiologist or neurologist.
This study was approved by the University of Iowa’s
Institutional Review Board, and all participants provided
informed consent prior to participation.
Tasks
Participants were informed that they would be asked to rest
quietly with their eyes open on two occasions, and to meditate
(or alternatively, to relax) with their eyes closed on two occasions.
The instruction to keep the eyes open or closed was chosen to
reflect the manipulation reported in Dimsdale and Mills (2002).
It was also chosen to improve the face validity of the meditation
and relaxation conditions, as these activities are typically taught
and practiced with the eyes closed. Meditators were asked to
engage in their usual daily meditation practice for a period of
15–20min during the meditation condition. Since the Kundalini
tradition offers many different types of meditations deriving
different types of effects, Kundalini meditators were asked to
select a specific meditation practice that they had found helped
them decrease their level of bodily arousal in the past. Since
the Vipassana tradition does not provide such an approach,
Vipassana meditators were simply asked to engage in their
usual meditation practice. Non-meditators were instructed in the
performance of a cognitive relaxation strategy for a period of 15–
20min during the relaxation condition. Specifically, they were
asked to engage in a relaxation practice they had found useful
for themselves in the past, one that would help them to “relax
your mind and body, help you slow your thoughts, slow your
breathing, and slow your heart rate.” If a non-meditator reported
no such a strategy, they were given the option to perform one
or any combination of several relaxation strategies including
(1) reliving a pleasant memory, such as a warm day at the
beach, (2) replaying their favorite song internally, (3) completely
relaxing their musculature and/or (4) slowing their breathing.
These strategies were selected with the aim of facilitating
elicitation of the relaxation response (Benson et al., 1974). Non-
meditators were specifically instructed to avoid falling asleep
during the relaxation practice, despite any inclinations that might
arise.
During the rest conditions both groups were instructed
to avoid engaging in their meditation/relaxation practice, and
instead, to explore their everyday thoughts (for example,
thoughts about activities from the recent past such as what they
had done the day before, or thoughts about potential future
activities such as what they would do once the study had been
concluded).
All participants were informed that they would be receiving
isoproterenol or saline at some points during the entire session,
but that neither they nor the experimenter would know when
the nurse administered a particular agent. The room in which
the study took place was kept quiet and was dimly lit throughout
duration of the study to minimize distractions. Participants were
seated in a padded chair, with a curtain draped over the arm
containing the intravenous line, in order to reduce distraction
and to preserve the blinding.
To assess task validity, after each meditation condition was
complete, participants were asked to “rate how similar your
meditation practice just now compares to your meditation
practice in general,” on a scale from 1 (“not at all the same”)
to 5 (“completely the same”). Non-meditators were also asked
to rate their relaxation practice in a similar fashion, using
the same scale. If they reported never having practiced the
specific instructed relaxation condition, they were asked to relate
their experience to other events where they had felt a state of
relaxation.
Infusion Protocol
Two sets of standard bolus isoproterenol infusion protocols and
two sets of matched saline infusion protocols were administered.
The isoproterenol protocols consisted of sequentially increasing
bolus isoproterenol doses of 0.1, 0.5, 1.0, 2.0, and 4.0 (mcg),
delivered 3.5min apart. The saline protocols consisted of five
identically delivered bolus infusions of saline.
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Infusion Delivery
Each infusion (isoproterenol and saline) consisted of two 3
milliliter (ml) bolus infusions delivered sequentially through
an intravenous catheter. During isoproterenol infusions, a 3ml
bolus containing the specified dose was delivered, immediately
followed by a 3ml bolus of saline to flush the line. During
saline infusions, a 3ml bolus of saline was delivered, immediately
followed by an additional 3ml bolus of saline. Both bolus
volumes were administered in entirety within a 15 s period by a
nurse from the General Clinical Research Center. This method of
delivery minimized the participant’s ability to use external cues
to distinguish between the different infusion types, and ensured
rapid and standardized systemic introduction of isoproterenol.
Procedure
The infusion protocol order was pseudorandomized and single
blinded. This was necessitated by practical considerations: in
order to ensure the safety of isoproterenol administration,
a physician was required to be present during the first
round of infusions. Due to constraints in the physician’s
schedule, a majority of the time the first condition consisted of
isoproterenol infusions. However, the remaining task selection
process (for example, isoproterenol plus rest vs. isoproterenol
plus meditation) remained randomized, and was determined
by the nurse administering the infusions. The remaining three
infusion conditions were completely randomized.
Psychophysiological Measures
Heart rate was continuously measured throughout all infusions,
from a lead II electrocardiogram (MP100 acquisition unit, Biopac
Systems, Inc.), at a sampling rate of 200Hz. All artifacts affecting
the cardiac waveform (e.g., movement related and cardiac, such
as premature ventricular contractions) were visually identified
and manually removed.
Several measures of heart rate were derived from the
instantaneous cardiac waveform. These measures were divided
across three epochs of specific relevance to the timeline of heart
rate changes induced by isoproterenol (Figure 1). The first epoch
consisted of a 30 s interval starting immediately after the onset
of each infusion. This reflects a period when bolus isoproterenol
induced heart rate changes are unlikely to occur. The second
epoch consisted of a 90 s interval beginning 30 s after infusion
administration. This reflects a period when bolus isoproterenol
induced heart rate changes are most likely to occur. The third
epoch consisted of a 60 s period beginning immediately after
the end of the second epoch. This interval reflects a period
when the heart rate is nearing baseline or has already returned
back to baseline. These three epochs combine to represent the
3min following each infusion onset, when the probability of
isoproterenol induced changes in heart rate are maximal. Because
the participant could hear the nurse was preparing the next
infusion during the final 30 s period (of the 3.5min separating
each infusion), this period was not included in the analysis to
remove any potential influence of this preparatory period on the
heart rate.
Within each epoch, four measures were obtained. (1) Mean
heart rate change. This was determined for each participant by
FIGURE 1 | Epochs used to derive different measures of heart rate. This
example shows a typical heart rate response to a 2.0 mcg dose of
isoproterenol in a single subject.
subtracting the average heart rate during epoch 1 from epoch
2. This controls for any potential residual elevations in baseline
heart rate that might occur following increasing doses, and
provided a reliable estimate of changes induced by isoproterenol
administration. (2) Mean heart rates for each participant were
determined across epochs 1, 2, and 3. This provided a measure
of average heart rate over the entire window of response to
isoproterenol. (3) The lowest heart rates occurring for each
participant within a 3 s period throughout epochs 1, 2, and 3. This
provided a measure of the floor effect for the heart rate response
to isoproterenol. (4) The highest heart rates occurring for each
participant within a 3-s period were identified across epochs 1, 2,
and 3. This provided a measure of the ceiling effect of the heart
rate response to isoproterenol.
Finally, heart rate and blood pressure were measured with
an automated non-invasive blood pressure monitoring device
(inflatable cuff wrapped around the dominant arm) similar to
what was likely used during the Dimsdale and Mills (2002)
study1. These latter measures were initiated 30 s after the start of
each infusion, in an effort tomirror the type ofmeasurement used
by Dimsdale andMills (2002). Due to variability in the amount of
time taken for the machine to generate a blood pressure reading,
each measure with this device was obtained approximately 60–
80 s after each infusion onset (maximum range observed: 58–93 s
after initiating measurement).
Data Analysis
Continuous data were analyzed using general linear models
(GLM) with repeated measures, with group (meditator, non-
meditator) as the between subjects factor and with condition
(isoproterenol plus meditation or relaxation, isoproterenol plus
rest, saline plus meditation or relaxation, saline plus rest) and
dose (isoproterenol, saline) as the within subjects factors. In
the GLM analysis, the meditation vs. rest contrast is explicitly
evaluated in the condition term. Therefore, the pertinent
measures determining whether meditators show differences in
their autonomic responses during meditation vs. rest were tested
by the group x condition, and by the group x condition x
dose interactions. All repeated measures tests were assessed for
1These measures were incorporated after several participants had been tested. As
a result, data for the full sample are unavailable (measures were collected from 11
meditators and 13 non-meditators).
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violations of the sphericity assumption, and when violated, were
corrected with the Huynh-Feldt method. In these instances the
corrected p-values are reported, along with the Huynh-Feldt
epsilon (ε) correction.
Results
Participants
Meditators reported significantly more years of meditation
practice t(28) = 3.90, p = 0.002, hours of cumulative meditation
practice t(28) = 3.07, p = 0.008, and days of retreat experience
t(28) = 2.31, p = 0.037, than non-meditators. The groups did not
differ with respect to age t(28) = 0.15, p = 0.88, body mass index
t(28) = −0.63, p = 0.53, or education t(28) = 1.64, p = 0.11. The
groups also did not differ with respect to baseline levels of anxiety
(assessed via the Beck Anxiety Inventory) t(28) = 1.39, p =
0.18, or depression (assessed via the Beck Depression Inventory)
t(28) = 0.33, p = 0.74.
Mean Heart Rate Change
As expected, we observed a significant effect of condition
F(1, 3) = 140.22, p < 0.0001, η
2
p = 0.83, ε = 0.780,
observed power = 1.00, and dose F(1, 4) = 68.5, p < 0.0001,
η
2
p = 0.71, ε = 0.554, observed power = 1.00, on the mean
heart rate response to isoproterenol. There was a significant
interaction between condition and dose F(1, 12) = 68.54, p <
0.0001, η2p = 0.59, ε = 0.737, observed power = 1.00, such
that increases in heart rate occurred at increasing doses of
isoproterenol (but not saline) administration. However, despite
these changes, there were no group differences in the heart rate
response to isoproterenol. There was no effect of group F(1, 28) =
2.97, p = 0.10, η2p = 0.10, observed power = 0.384, and there
were no interactions between condition and group F(1, 3) = 0.21,
p = 0.84, η2p = 0.01, observed power = 0.088, between dose
and group F(1, 4) = 0.21, p = 0.84, η
2
p = 0.01, observed
power = 0.093, or between condition and group and dose
F(1, 12) = 0.82, p = 0.60, η
2
p = 0.03, observed power = 0.482,
suggesting that the heart rate increases induced by isoproterenol
were not statistically different between the groups (Figure 2A).
Mean average heart rate changes and associated 95% confidence
intervals are displayed in Table 2.
Mean Heart Rate
Epoch 1
We did not find an effect of condition on the average heart
rate during epoch 1, F(1, 3) = 0.39, p = 0.76, η
2
p = 0.01,
observed power= 0.12, but did observe a significant effect of dose
F(1, 4) = 4.74, p = 0.008, η
2
p = 0.15, ε = 0.616, observed power=
0.80. There was also a significant interaction between condition
and dose F(1, 12) = 4.41, p < 0.0001, η
2
p = 0.14, ε = 0.772,
observed power = 0.99, suggesting that increases in mean heart
rate during epoch 1 occurred at increasing doses of isoproterenol
(but not saline) administration. However, despite these changes,
there were no group differences in heart rate during this period.
There was no effect of group F(1, 28) = 1.20, p = 0.28, η
2
p = 0.04,
observed power = 0.19, and there were no interactions between
condition and group F(1, 3) = 2.00, p = 0.12, η
2
p = 0.07,
observed power = 0.50, between dose and group F(1, 4) = 0.33,
p = 0.76, η2p = 0.01, observed power = 0.12, or between
condition and group and dose F(1, 12) = 0.74, p = 0.68, η
2
p =
0.03, observed power= 0.43, suggesting that the mean heart rate
increases observed for increasing doses of isoproterenol during
epoch 1 were not statistically different between groups. Average
heart rate changes and associated 95% confidence intervals are
displayed in Table 3. The finding of dose related increases during
this epoch reflects that fact that some of the heart rate changes
induced by isoproterenol (particularly at the higher doses) began
occurring early, as was observed in several participants.
Epoch 2
We observed a significant effect of condition on the average heart
rate during epoch 2, F(1, 3) = 84.19, p < 0.0001, η
2
p = 0.75,
observed power = 1.00, as well as for dose F(1, 4) = 84.19,
p < 0.0001, η2p = 0.75, ε = 0.402, observed power = 1.00.
There was also a significant interaction between condition and
dose F(1, 12) = 72.91, p < 0.0001, η
2
p = 0.72, ε = 0.330,
observed power = 1.00, suggesting that increases in mean heart
rate during epoch 2 occurred at increasing doses of isoproterenol
(but not saline) administration. However, despite these changes,
there were again no group differences in heart rate during this
period. There was no effect of group F(1, 28) = 0.65, p =
0.43, η2p = 0.02, observed power = 0.12, and there were no
interactions between condition and group F(1, 3) = 2.00, p =
0.12, η2p = 0.07, observed power = 0.37, between dose and
group F(1, 4) = 1.44, p = 0.24, η
2
p = 0.05, observed power
= 0.16, or between condition and group and dose F(1, 12) =
0.70, p = 0.59, η2p = 0.02, observed power = 0.41, suggesting
that the mean heart rate increases observed for increasing doses
of isoproterenol during epoch 2 were not statistically different
between groups (Figure 2B and Table 4).
Epoch 3
We observed a significant effect of condition on the average heart
rate during epoch 3, F(1, 3) = 8.30, p < 0.0001, η
2
p = 0.23,
observed power = 0.98, as well as for dose F(1, 4) = 30.66,
p < 0.0001, η2p = 0.52, ε = 0.440, observed power = 1.00.
There was also a significant interaction between condition and
dose F(1, 12) = 20.72, p < 0.0001, η
2
p = 0.43, ε = 0.418,
observed power = 1.00, suggesting that increases in mean heart
rate during epoch 3 occurred at increasing doses of isoproterenol
(but not saline) administration. However, despite these changes,
there were no group differences in heart rate during this period.
There was no effect of group F(1,28) = 0.92, p = 0.35, η
2
p = 0.03,
observed power = 0.15, and there were no interactions between
condition and group F(1, 3) = 1.68, p = 0.18, η
2
p = 0.06,
observed power = 0.43, between dose and group F(1, 4) = 0.93,
p = 0.39, η2p = 0.03, observed power = 0.29, or between
condition and group and dose F(1, 12) = 0.65, p = 0.67, η
2
p =
0.02, observed power= 0.38, suggesting that the mean heart rate
increases observed for increasing doses of isoproterenol during
epoch 3 were not statistically different between groups. The
finding of dose related increases during this epoch reflects that
fact that some of the heart rate changes induced by isoproterenol
(particularly at the higher doses) were still present and in the
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FIGURE 2 | Mean heart rates for both groups during
mediation/relaxation and rest. (A) Mean heart rate change (epoch
2minus epoch 1). (B) Mean heart rate during epoch 2. (C) Mean heart rates
measured via automated blood pressure monitor. For purposes of clarity,
mean values are displayed without error bars, and the relaxation condition for
the non-meditators is labeled as meditation.
process of returning to baseline, as was observed in several
participants (Table 5).
Highest and Lowest Heart Rates
The pattern of findings reported above also held true for the
highest and lowest heart rates observed during epochs 1, 2,
and 3. Specifically, increases in the highest (and lowest) heart
rates occurred for conditions containing increasing doses of
isoproterenol (but not saline), in the absence of any group
differences whatsoever. In the interest of brevity the relevant
statistics have not been reported here, but rather, the reader is
referred to Figure 3.
Automated Heart Rate and Blood Pressure
Automated Heart Rate
We observed a significant effect of condition on the automated
measure of heart rate F(1, 3) = 115.88, p < 0.0001, η
2
p = 0.84,
ε = 0.813, observed power= 1.00, as well as dose F(1, 4) = 74.42,
p < 0.0001, η2p = 0.77, ε = 0.909, observed power = 1.00.
There was also a significant interaction between condition and
dose F(1, 12) = 40.31, p < 0.0001, η
2
p = 0.65, ε = 0.438,
observed power = 1.00, suggesting that increases in automated
heart rate occurred at increasing doses of isoproterenol (but not
saline) administration. There were again no group differences
in heart rate during this period. There was no effect of group
F(1, 28) = 0.06, p = 0.80, η
2
p = 0.00, observed power = 0.06,
and there were no interactions between condition and group
F(1, 3) = 1.02, p = 0.38, η
2
p = 0.04, observed power = 0.27,
between dose and group F(1, 4) = 2.12, p = 0.09, η
2
p = 0.09,
observed power = 0.61, or between condition and group and
dose F(1, 12) = 1.19, p = 0.32, η
2
p = 0.05, observed power =
0.68, suggesting that the mean heart rate increases observed for
increasing doses of isoproterenol with the automated measure
were similar between the groups (Figure 2C).
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TABLE 2 | Average heart rate changes and 95% confidence intervals across all conditions.
Average HR change
Dose (mcg) Non-meditators 95% CI Meditators 95% CI
Mean SE Lower Upper Mean SE Lower Upper
ISO + RELAXATION ISO + MEDITATION
0.1 0.74 0.84 −0.99 2.47 0.97 0.84 −0.76 2.7
0.5 4.33 0.77 2.74 5.91 2.6 0.77 1.03 4.2
1 8.02 1.03 5.91 10.13 6.2 1.03 4.09 8.3
2 12.91 1.63 9.58 16.25 11.11 1.63 7.79 14.45
4 17.93 2.26 13.3 22.56 17.27 2.26 12.64 21.89
ISO + REST ISO + REST
0.1 1.97 0.65 0.65 3.31 1.82 0.65 0.48 3.15
0.5 5.01 0.85 3.28 6.74 3.97 0.85 2.24 5.7
1 6.99 0.76 5.44 8.53 6.28 0.76 4.73 7.82
2 12.22 1.39 9.38 15.06 10.89 1.39 8.05 13.73
4 18.85 1.54 15.71 22.02 15.44 1.54 12.28 18.59
SALINE + RELAXATION SALINE + MEDITATION
0.1 0 0.96 −1.96 1.97 −1.04 0.96 −3 0.92
0.5 0.89 0.66 −0.47 2.2 −1.17 0.66 −2.52 0.18
1 0.86 0.51 −0.19 1.91 −1.03 0.51 −2.08 0.02
2 0.76 0.52 −0.31 1.84 −0.22 0.52 −1.29 0.85
4 −1.54 1.04 −3.67 0.6 −0.88 1.04 −3.02 1.25
SALINE + REST SALINE + REST
0.1 0.85 0.59 −0.37 2.06 −0.13 0.59 −1.35 1.08
0.5 0.58 0.52 −0.49 1.65 0.33 0.52 −0.74 1.4
1 0.69 0.65 −0.62 2 0.88 0.64 −0.42 2.19
2 0.39 0.9 −1.47 2.24 −0.9 0.9 −2.75 0.95
4 0.82 0.61 −0.44 2.07 0.74 0.61 −0.51 2
Systolic Blood Pressure
We did not observe a significant effect of condition F(1, 3) =
0.03, p = 0.99, η2p = 0.00, observed power = 0.06, but
did observe a significant effect of dose F(1, 4) = 4.35, p =
0.006, η2p = 0.17, ε = 0.820, observed power = 0.82, on the
automated measure of systolic blood pressure. There was no
interaction between condition and dose F(1, 12) = 1.74, p < 0.08,
η
2
p = 0.07, observed power = 0.87, suggesting that changes
in systolic blood pressure were not influenced by isoproterenol
administration. No group differences in systolic blood pressure
were observed. There was no effect of group F(1,28) = 0.71,
p = 0.41, η2p = 0.03, observed power = 0.13, and there were
no interactions between condition and group F(1, 3) = 0.80,
p = 0.50, η2p = 0.04, observed power = 0.21, between dose and
group F(1, 4) = 1.52, p = 0.21, η
2
p = 0.07, observed power =
0.45, or between condition and group and dose F(1, 12) = 1.03,
p = 0.42, η2p = 0.05, observed power = 0.59. These decreases
in systolic blood pressure were similar for both groups and
appeared to occur during the first few doses, irrespective of
condition, suggesting that these effects were likely not related to
isoproterenol (Figure 4A).
Diastolic Blood Pressure
We observed a significant effect of condition F(1, 3) = 25.37, p <
0.0001, η2p = 0.54, observed power = 1.00, and dose F(1, 4) =
28.58, p < 0.0001, η2p = 0.57, ε = 0.653, observed power
= 1.00 on the automated measure of diastolic blood pressure.
There was also a significant interaction between condition and
dose F(1, 12) = 12.43, p < 0.0001, η
2
p = 0.36, ε = 0.692,
observed power= 1.00, suggesting that changes in diastolic blood
pressure occurred at increasing doses of isoproterenol (but not
saline) administration. There were again no group differences in
diastolic blood pressure. There was no effect of group F(1, 28) =
0.65, p = 0.43, η2p = 0.03, observed power = 0.12, and there
were no interactions between condition and group F(1, 3) = 0.29,
p = 0.82, η2p = 0.01, observed power = 0.10, between dose and
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TABLE 3 | Average heart rates during epoch 1, including 95% confidence intervals.
Average HR—epoch 1
Dose (mcg) Non-meditators 95% CI Meditators 95% CI
Mean SE Lower Upper Mean SE Lower Upper
ISO + RELAXATION ISO + MEDITATION
0.1 66.47 2.54 61.27 71.77 71.86 2.54 66.67 77.06
0.5 66.26 2.83 60.46 72.07 72.92 2.83 67.11 78.72
1 66.37 2.68 60.89 71.86 71.97 2.68 66.49 77.46
2 67.48 2.76 61.83 73.12 72.22 2.76 66.57 77.87
4 69.4 3.12 63 75.8 75.05 3.12 68.65 81.45
ISO + REST ISO + REST
0.1 66.18 2.52 61.03 71.35 69.09 2.52 63.92 74.25
0.5 67.32 2.59 62.02 72.2 69.74 2.59 64.44 75.04
1 68.46 2.6 64.12 73.79 70.98 2.6 65.65 76.32
2 67.98 2.65 62.58 73.29 71.28 2.64 65.87 76.69
4 70.45 2.97 64.37 76.53 73.11 2.97 67.03 79.19
SALINE + RELAXATION SALINE + MEDITATION
0.1 68.29 3.3 61.54 75.04 72.96 3.3 66.2 79.71
0.5 66.91 2.72 61.33 72.49 72.72 2.72 67.14 78.3
1 66.87 2.71 61.32 72.43 72.01 2.71 66.46 77.57
2 67.07 2.77 61.39 72.74 70.81 2.77 65.13 76.49
4 68.24 3.1 61.88 74.59 71.7 3.1 65.34 78.06
SALINE + REST SALINE + REST
0.1 67.26 2.78 61.56 72.96 72.16 2.78 66.46 77.86
0.5 67.73 2.67 62.27 73.19 70.91 2.67 65.45 76.37
1 68.00 2.73 62.42 73.59 70.42 2.73 64.83 76
2 67.94 2.87 62.05 73.83 71.43 2.87 65.54 77.32
4 67.31 2.58 62.02 72.59 71.1 2.58 65.81 76.38
group F(1, 4) = 0.36, p = 0.76, η
2
p = 0.02, observed power =
0.13, or between condition and group and dose F(1, 12) = 0.45,
p = 0.90, η2p = 0.02, observed power = 0.25. These findings
suggest decreases in diastolic blood pressure were similar for
both groups at increasing doses of isoproterenol (Figure 4B).
Such a decrease in diastolic blood pressure is consistent with the
vasodilatory effects of isoproterenol.
Individual Heart Rates
Given the absence of group effects, an examination of individual
heart rate changes during the isoproterenol plus meditation
condition was performed. The goal was to identify whether
any reductions in heart rate similar those reported in Dimsdale
and Mills (2002) had occurred in individual meditators or non-
meditators. At the individual level, we examined mean heart rate
changes during epoch 2, mean heart rate during epoch 2, and
lowest and highest heart rate during epoch 2 derived from the
continuous heart rate waveform during the isoproterenol plus
meditation/relaxation and isoproterenol plus rest conditions.
Based on the hypothesis that meditation would result in a
reduced response to isoproterenol, individual meditators and
non-meditators displaying the lowest responses were selected for
comparison with their respective groups. As Figure 5A indicates,
there were individuals in each group who displayed a reduced
heart rate response and reduced average heart rates relative to
their group averages. Similarly, there were individuals in each
group who displayed reduced heart rate maxima and minima
when compared with their group averages (Figure 5B). However,
although these reflect large differences in the magnitude of
the response to isoproterenol (compared to the respective
group mean), only one individual (a meditator) appeared to
display a reduced heart rate at increasing doses, and only when
using the criterion for lowest heart rate observed during a 3 s
period.
Subjective Experience
Similarity ratings of the meditation and relaxation practices did
not differ between the groups F(1, 25) = 0.03, p = 0.86, η
2
p =
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TABLE 4 | Average heart rates during epoch 2, including 95% confidence intervals.
Average HR—epoch 2
Dose (mcg) Non-meditators 95% CI Meditators 95% CI
Mean SE Lower Upper Mean SE Lower Upper
ISO + RELAXATION ISO + MEDITATION
0.1 67.21 2.55 61.98 72.43 72.84 2.55 67.61 78.06
0.5 70.59 2.71 65.04 76.13 75.53 2.71 69.98 81.08
1 74.39 2.95 68.35 80.43 78.17 2.95 72.13 84.21
2 80.39 3.5 73.22 87.55 83.34 3.5 76.17 90.5
4 87.33 4.14 78.87 95.8 92.32 4.14 83.85 100.79
ISO + REST ISO + REST
0.1 68.17 2.51 63.03 73.31 70.9 2.51 65.76 76.04
0.5 72.34 2.64 66.93 77.74 73.71 2.64 68.31 79.12
1 75.44 2.84 69.62 81.26 77.26 2.84 71.44 83.08
2 80.21 3.19 73.66 86.75 82.17 3.19 75.63 88.71
4 89.31 3.51 82.13 96.49 88.55 3.51 81.37 95.73
SALINE + RELAXATION SALINE + MEDITATION
0.1 68.39 2.9 62.36 74.23 71.92 2.9 65.98 77.85
0.5 67.79 2.69 62.23 73.3 71.55 2.69 66.04 77.06
1 67.73 2.8 62.01 73.45 70.99 2.8 65.26 76.71
2 67.83 2.75 62.2 73.46 70.59 2.75 65.96 76.22
4 66.7 2.73 61.11 72.29 70.82 2.73 65.23 76.4
SALINE + REST SALINE + REST
0.1 68.10 2.77 62.44 73.77 72.03 2.77 66.36 77.7
0.5 68.31 2.63 62.93 73.7 71.24 2.63 65.86 76.63
1 68.69 2.69 63.19 74.19 71.3 2.66 65.8 76.8
2 68.33 2.66 62.89 73.77 70.53 2.66 65.09 75.97
4 68.12 2.8 62.38 73.86 71.84 2.8 66.1 77.58
0.001, observed power = 0.0542. The meditation and relaxation
practices appeared to be rated as more similar to the usual
practice during the saline infusion condition, but this difference
was not statistically significant F(1, 1) = 2.18, p = 0.15, η
2
p =
0.08, observed power= 0.30.
Post Analysis
Since a heterogeneously recruited sample of meditators could
potentially result in differential heart rate responses during
meditation, we subsequently evaluated the responses of the
Kundalini and Vipassana practitioners separately, and in
comparison to each other.
Vipassana vs. Healthy Comparison
During the meditation condition there was no effect of group
F(1, 24) = 1.31, p = 0.26, η
2
p = 0.05, observed power = 0.20,
2Data were missing from 3 healthy comparison participants.
and there were no interactions between condition and group
F(1, 1) = 0.002, p = 0.98, η
2
p = 0.00, observed power =
0.05, or between condition and group and dose F(1, 4) = 0.10,
p = 0.98, η2p = 0.004, observed power= 0.07. This suggests that
during both meditation conditions (saline and isoproterenol)
the Vipassana meditators displayed similar average heart rate
increases as healthy comparisons.
Kundalini vs. healthy Comparison
During the meditation condition there was no effect of group
F(1, 17) = 2.1, p = 0.17, η
2
p = 0.11, observed power = 0.27,
and there were no interactions between condition and group
F(1, 1) = 0.006, p = 0.94, η
2
p = 0.00, observed power =
0.05, or between condition and group and dose F(1, 4) = 1.58,
p = 0.19, η2p = 0.09, observed power = 0.46. This suggests that
during both meditation conditions (saline and isoproterenol)
the Kundalini meditators displayed similar average heart rate
increases as healthy comparisons.
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TABLE 5 | Average heart rates during epoch 3, including 95% confidence intervals.
Average HR—epoch 3
Dose (mcg) Non-meditators 95% CI Meditators 95% CI
Mean SE Lower Upper Mean SE Lower Upper
ISO + RELAXATION ISO + MEDITATION
0.1 66.58 2.58 61.29 71.87 71.57 2.58 66.28 76.85
0.5 66.28 2.71 60.73 71.82 71.7 2.71 66.16 77.25
1 68.1 2.74 62.49 73.71 72.5 2.74 66.89 78.11
2 70.59 3.15 64.13 77.05 75.11 3.15 68.66 81.57
4 73.94 3.67 66.43 81.45 81.28 3.67 73.77 88.79
ISO + REST ISO + REST
0.1 67.88 2.55 62.66 73.1 71.8 2.55 66.57 77.02
0.5 68.38 2.63 62.99 73.77 70.67 2.63 65.28 76.06
1 68.75 2.65 63.32 74.19 70.86 2.65 65.43 76.3
2 71.47 3.04 65.25 77.69 75.57 3.04 69.35 81.79
4 77.07 3.33 70.24 83.9 80.35 3.33 73.52 87.18
SALINE + RELAXATION SALINE + MEDITATION
0.1 67.93 2.74 62.31 73.54 71.97 2.74 66.34 77.57
0.5 68.06 2.67 62.6 73.52 71.85 2.67 66.39 77.31
1 68.58 2.7 63.04 74.12 71.2 2.7 65.66 76.74
2 67.89 2.78 62.2 73.58 70.39 2.78 64.7 76.08
4 66.48 2.69 60.97 72 70.09 2.69 65.57 75.6
SALINE + REST SALINE + REST
0.1 68.12 2.6 62.8 73.44 71.78 2.6 66.46 77.1
0.5 68.67 2.67 63.19 74.14 71.24 2.67 65.77 76.72
1 69.73 2.53 64.54 74.93 71.04 2.53 65.85 76.23
2 68.38 2.66 62.94 73.83 71.83 2.66 66.39 77.27
4 69.81 2.77 64.14 75.47 72.15 2.77 66.49 77.82
Kundalini vs. Vipassana
During the meditation condition there was no effect of group
F(1, 13) = 0.11, p = 0.75, η
2
p = 0.008, observed power = 0.06,
and there were no interactions between condition and group
F(1, 1) = 0.001, p = 0.98, η
2
p = 0.00, observed power = 0.05, or
between condition and group and dose F(1, 4) = 0.88, p = 0.48,
η
2
p = 0.06, observed power= 0.26. This suggests that during both
meditation conditions (saline and isoproterenol) the two groups
of meditators displayed similar average heart rate increases.
Discussion
As expected, bolus isoproterenol infusions produced dose-
dependent increases in heart rate in both groups during
a condition of rest. However, meditators did not display
lowered heart rate responses to isoproterenol while practicing
meditation. Both meditators and non-meditators displayed
similar dose dependent increases in heart rate during conditions
of isoproterenol plus rest, and during isoproterenol plus
meditation/relaxation. The lack of group differences in heart rate
was reliable. It was observed for five different measures of heart
rate (mean heart rate change, mean heart rate, lowest heart rate
during a 3 s period, highest heart rate during a 3 s period, and
via automated heart rate monitor), and throughout three epochs
that captured the entire time span over which isoproterenol
induced changes occur. Equivalent decreases in diastolic blood
pressure were also observed in both groups following increasing
doses of isoproterenol. These decreases are consistent with the
known vasodilatory effects of isoproterenol on lowering diastolic
blood pressure. We do not consider these to be related to the
meditation intervention, as they occurred in both isoproterenol
conditions. Non-meditators did not display lowered heart rates
when practicing a relaxation condition, which was predicted.
Since the Dimsdale and Mills (2002) study reported a
finding in a single individual, we examined individual heart rate
responses within in each group of participants. Of the measures
utilized, there was only one participant who demonstrated an
appreciable reduction in heart rate during the meditation plus
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FIGURE 3 | Highest and lowest heart rates for both groups during
epoch 2. (A) Highest heart rates observed during a 3 s period, averaged
across each group (ceiling effect). (B) Lowest heart rates observed during a
3 s period, averaged across each group (floor effect). For purposes of clarity,
mean values are displayed without error bars, and the relaxation condition for
the non-meditators is labeled as meditation.
isoproterenol condition similar to that reported by Dimsdale and
Mills (2002) (i.e., a 17 bpm decrease in heart rate from the lowest
to the highest dose). This finding occurred in a meditator, but it
was only observed with one measure, the lowest heart rate, which
is also the least reliable index of the response to isoproterenol.
This finding was no longer present when more robust measures
of the heart rate response to isoproterenol, such as the average
heart rate and average heart rate change, were examined in the
same individual. Thus, it seems unlikely that the individual effect
reported by Dimsdale and Mills (2002), although intriguing,
generally applies to individuals practicing meditation.
Several potential factors might explain the discrepancy in
findings between the two studies. First, individual variability in
heart rate responses might explain their observation of lowered
heart rate in one subject. We observed considerable variability
in heart rate responses to isoproterenol even when using a
continuous measure, with select individuals from both groups
exhibiting attenuated heart rate responses to isoproterenol. A
second and related reason could bemeasurement error. Dimsdale
and Mills (2002) did not utilize a continuous measure of heart
rate in their original study, and it is unclear when the automated
monitor they utilized actually captured their meditator’s heart
rate. Although they report that heart rate was measured 60 s after
the infusion was delivered, it is possible that there was enough
measurement variability to result in missing the heart rate epoch
of interest. In the present study, we observed large variability
in the output of the automated heart rate measurement when
using the blood pressure monitoring device (e.g., 58–93 s after
initiatingmeasurement), which is long enough to potentiallymiss
capturing an individual’s heart rate response. It is also possible
that the window of measurement of the automated heart rate
monitor was too brief. In the current study, we observed the
largest reductions in heart rate response during a momentary
measure, the lowest heart rate during a 3 s period, which provides
some plausibility to this theory. Third, their meditator was not
formally trained, and indicated that she would often enter such
deep states that she would need to set an alarm clock to rouse
her from meditation. Thus, it is possible that this individual
likened sleep (or some other altered state of consciousness) with
meditation, and that the observed effect had nothing to do with
meditation but a different process worth understanding further.
However, despite these potential methodological and conceptual
considerations, the participant in Dimsdale and Mills’ study did
demonstrate a heart rate increase at the 1.0 mcg dose, followed by
two successive decreases below her resting heart rate. Assuming
this was not a spurious finding, such a profound decrease in
heart rate could also occur during an episode of increased vagal
output (as suggested by the authors). Neurocardiogenic syncope
is one example of such an increase in vagal output. These episodes
are usually preceded by an increase in sympathetic tone (as
was observed in the meditator at the 1.0 mcg dose) and can
even be triggered by isoproterenol (Kikushima et al., 1999).
These episodes are often foreshadowed by symptoms such as
lightheadedness, nausea, warmth, pallor and/or sweating, and
although the meditator denied experiencing a subset of these
(nausea, dizziness or fainting), it is possible that she was not
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FIGURE 4 | Blood pressure for both groups during
meditation/relaxation and rest. (A) Systolic blood pressure measured via
automated blood pressure monitor. (B) Diastolic blood pressure measured
via automated blood pressure monitor. For purposes of clarity, mean values
are displayed without error bars, and the relaxation condition for the
non-meditators is labeled as meditation.
aware of these symptoms given the fact that she was in a
meditative state described as so deep as to require rousing with
an alarm clock. Since heart rate was the only autonomic measure
reported in that study, it is difficult to determine whether such a
reflex occurred. Evaluating this particular meditator’s (or others
the future) cardiovascular responses to upright tilt table testing
(perhaps even incorporating isoproterenol) could be useful to
exclude this as a possibility. Another possibility is that respiratory
modulation could have played a role in the observed heart rate
changes, as respiratory induced changes in heart rate variability
have been observed in meditators (Peng et al., 2004). We did not
examine this possibility as it was outside the scope of inquiry in
our study.
There are several limitations associated with the present
study. First, the meditation practice was investigated under
highly artificial circumstances. Meditators were meditating in
a novel environment, with an intravenous line placed, were
attached to various recording devices and were seated next
to two individuals who were observing them throughout the
study. Despite efforts to facilitate the practice, such as a curtain
between the investigators and participant, and a dimly lit,
quiet room, it cannot be claimed that the meditation and
relaxation conditions took place in the usual environment.
Second, the current study does not take into account the potential
influence of testing anxiety, that is, concern on the part of
the meditators about “performing well.” Although meditators
did not voice any such concerns, and did not differ from
the non-meditators in questionnaire measures of anxiety, this
possibility cannot be ruled out. A third limitation is the fact
that the meditation plus saline conditions did not appear to
lower the heart rate substantially. This could again be due to the
artificiality of the environment, thus preventing meditators from
authentically engaging in their practice and displaying increased
parasympathetic indices. However, retrospective ratings of the
quality of the meditation practice indicated that meditators
found their meditation practice during the infusions to be
predominantly similar to their daily practice, reducing this as
a possibility. The lack of heart rate reductions during saline
could also be related to the type of meditation participants
practiced. For example, some meditations are suggested to
increase cardiovascular states whereas others are suggested to
decrease them (Amihai and Kozhevnikov, 2014). Since most
meditators were not instructed to use their meditation practice
to reduce their heart rate (this would have been seen by the
Vipassana practitioners as constraining and interfering with
the meditation practice), it is possible that the mediators were
performing the former type of meditation. Reports from the
meditators about the nature and quality of their practice did not
seem to indicate this as a possibility.
It is also possible that the lack of attenuated autonomic
responses in the current study could be related to a non-
ideal sample of meditators and/or a non-ideal meditation
practice. For example, since the majority of the meditators
came from a Vipassana background, their default meditation
practice may not be intended to have effects on autonomic
state. This argument is somewhat limited by the fact that
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FIGURE 5 | Global and individual outlier heart rate changes
during isoproterenol conditions. (A) Global mean heart rate
change (epoch 2minus epoch 1), and global mean heart rate
observed during epoch 2 for all participants. (B) Global maximum
heart rate change and global minimum heart rate change observed
during epoch 2 for all participants. The green lines indicate the
meditator who displayed the lowest response during the isoproterenol
plus meditation condition. The blue lines indicate the non-meditators
who displayed the lowest response during the isoproterenol plus
relaxation condition. For purposes of clarity, the relaxation condition
for the non-meditators is labeled as meditation. Error bars represent
standard error of the mean.
Vipassana meditation techniques emphasize the cultivation
of quiescent and tranquil states of mind, and show some
evidence of altered sympatho-vagal balance (Krygier et al.,
2013). Alternatively, it is theoretically possible that the default
body scanning meditation practice practiced by the Vipassana
meditators in this study could have been similar to a form
of “open presence” rather than “focused attention” meditation.
Since the former type of meditation has been associated
with heightened arousal instead of relaxation, this might be
expected to induce an increased autonomic response during
meditation instead of a quiescent one. We observed a few
marginal interactions between condition and group on heart rate
with the meditators potentially exhibiting increased heart rates
during meditation, that might potentially support this possibility.
However, these non-significant effects were not consistently
observed across the numerous heart rate measures employed.
Further complicating this theoretical interpretation is evidence
suggesting that open presence meditation can be associated with
attenuated autonomic responses to startle challenges that probe
sympathetic reactivity (Levenson et al., 2012). We conclude there
is no direct evidence in the current study to support the notion
of differentially decreased or increased autonomic indices in the
meditators.
Another question about the current sample is whether the
absence of effect could have been due to an inexperienced
sample of meditators relative to the meditator in Dimsdale
and Mills (2002), as the minimum requirement was only 2
years of meditative experience. Direct comparison between
the studies is not possible, as the years of practice were not
provided in that report. However, the notion that duration of
practice is synonymous with meditative expertise is a matter of
ongoing debate. Previous investigations of long term meditators
have not always yielded evidence of increased ability, even
for aspects of internal sensory experience that are routinely
cultivated in Vipassana and Kundalini traditions (Khalsa et al.,
2008; Daubenmier et al., 2013). A larger issue is the fact
that the meditator described in that report was not formally
trained in any particular tradition, making it impossible to
select an appropriately representative group of meditators. In
the current study we recruited formally trained meditators from
multiple traditions, used extensive measurements of heart rate
response, and examined individual outlier responses in both
groups to determine whether there was specific evidence that
meditation was associated with a lowered heart rate. Though
some individuals displayed attenuated heart rate responses to
isoproterenol, we found no evidence differentiating meditators
from non-meditators.
A general point is that while these limitations warrant
consideration, many of them would be similarly imposed by any
empirical study of meditation and thus cannot be easily obviated.
If further investigations of the current topic were continued, one
helpful strategy would be to screen large samples of meditators
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to identify those individuals who can reliably demonstrate
enhanced autonomic regulatory capabilities, and then perform
detailed investigation into the cognitive and neurophysiological
mechanisms underlying such abilities.
We feel it is also important to note that the current findings do
not necessarily negate previously reported findings of decreased
autonomic tone following the practice of meditation. Although
our study appeared sufficiently powered to detect effects related
to the isoproterenol vs. saline conditions, and the impact of
different doses, there was lower power at the group level.
While replicating this approach with a larger sample would
help to address this limitation, the current results suggest
that any effects, even if found reliable at the population level,
would be small and would have limited consequence at the
individual level. The current findings also have limited bearing
on the effects of meditation on emotional experience or emotion
regulation, effects consistently perceived at the individual level
with training, as these constructs were not investigated. High
levels of adrenergic hormones are often associated with acute
anxiety, stress, anger, fear and hostility, and different forms
of meditation are routinely practiced by some individuals to
help ameliorate such experiences (Shirey, 2007; Robins et al.,
2012; Serpa et al., 2014). Determining the biological mechanisms
supporting those beneficial effects remains an important and
active area of inquiry, regardless of whether they are derived
from changes in autonomic reactivity or from changes in the
central nervous system. Overall, these results simply suggest
that the formal act of meditation may not be sufficient to
physiologically counteract certain forms of elevated levels of
peripheral cardiovascular adrenergic arousal or engender quicker
recovery from such arousal.
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